JP2020517704A - α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 - Google Patents

α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 Download PDF

Info

Publication number
JP2020517704A
JP2020517704A JP2019558417A JP2019558417A JP2020517704A JP 2020517704 A JP2020517704 A JP 2020517704A JP 2019558417 A JP2019558417 A JP 2019558417A JP 2019558417 A JP2019558417 A JP 2019558417A JP 2020517704 A JP2020517704 A JP 2020517704A
Authority
JP
Japan
Prior art keywords
day
bcl
labeled
days
hum195
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019558417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517704A5 (enExample
JPWO2018200841A5 (enExample
Inventor
ドラガン シシック，
ドラガン シシック，
Original Assignee
アクティニウム ファーマシューティカルズ インコーポレイテッド
アクティニウム ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティニウム ファーマシューティカルズ インコーポレイテッド, アクティニウム ファーマシューティカルズ インコーポレイテッド filed Critical アクティニウム ファーマシューティカルズ インコーポレイテッド
Publication of JP2020517704A publication Critical patent/JP2020517704A/ja
Publication of JP2020517704A5 publication Critical patent/JP2020517704A5/ja
Publication of JPWO2018200841A5 publication Critical patent/JPWO2018200841A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2019558417A 2017-04-28 2018-04-26 α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 Withdrawn JP2020517704A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491803P 2017-04-28 2017-04-28
US62/491,803 2017-04-28
PCT/US2018/029607 WO2018200841A1 (en) 2017-04-28 2018-04-26 Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020115411A Division JP2020158544A (ja) 2017-04-28 2020-07-03 α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法

Publications (3)

Publication Number Publication Date
JP2020517704A true JP2020517704A (ja) 2020-06-18
JP2020517704A5 JP2020517704A5 (enExample) 2020-08-13
JPWO2018200841A5 JPWO2018200841A5 (enExample) 2022-06-06

Family

ID=63919290

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019558417A Withdrawn JP2020517704A (ja) 2017-04-28 2018-04-26 α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法
JP2020115411A Withdrawn JP2020158544A (ja) 2017-04-28 2020-07-03 α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法
JP2023168404A Pending JP2023165952A (ja) 2017-04-28 2023-09-28 α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020115411A Withdrawn JP2020158544A (ja) 2017-04-28 2020-07-03 α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法
JP2023168404A Pending JP2023165952A (ja) 2017-04-28 2023-09-28 α線放射免疫療法薬とともにＢＣＬ－２インヒビターを使用してがんを処置するための方法

Country Status (8)

Country Link
US (4) US11364235B2 (enExample)
EP (1) EP3615047A4 (enExample)
JP (3) JP2020517704A (enExample)
CN (1) CN110612109A (enExample)
BR (1) BR112019022308A2 (enExample)
CA (1) CA3059752A1 (enExample)
MX (1) MX2019012660A (enExample)
WO (1) WO2018200841A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200841A1 (en) 2017-04-28 2018-11-01 Actinium Pharmaceuticals, Inc. Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
ES3039245T3 (en) * 2017-11-10 2025-10-20 Actinium Pharmaceuticals Inc Combination of radionuclide-conjugated antibodies for treatment of a hematological malignancies
CA3125197A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
KR20220125330A (ko) * 2020-01-10 2022-09-14 퓨전 파마슈티칼즈 인크. 지속 면역요법
US20240299600A1 (en) * 2020-09-08 2024-09-12 Actinium Pharmaceuticals, Inc. Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211232B2 (en) * 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US8487131B2 (en) * 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9777061B2 (en) * 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
BR112017005390A2 (pt) 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
US20160113925A1 (en) * 2014-10-22 2016-04-28 Emory University Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors
TW201639573A (zh) * 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
WO2017021963A1 (en) * 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
WO2018200841A1 (en) * 2017-04-28 2018-11-01 Actinium Pharmaceuticals, Inc. Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASCO EDUCATIONAL BOOK, 2014, PP.E126-E131, JPN6021025424, ISSN: 0004973736 *
BLOOD, 2014, VOL.124, NO.21, #118，<HTTPS://DOI.ORG/10.1182/BLOOD.V124.21.118.118>, JPN6022004501, ISSN: 0004973734 *
BLOOD, 2016, VOL.128, NO.22, #4050, JPN6021025426, ISSN: 0004973737 *
BLOOD, 2016, VOL.128, NO.22, #467, JPN6021025422, ISSN: 0004973735 *
STUDY NCT03867682 ON DATE: MARCH 6, 2019 (V1)，CLINICALTRIALS.GOV ARCHIVE[ONLINE]，2019年3月6日，[20, JPN6021025427, ISSN: 0004699227 *

Also Published As

Publication number Publication date
EP3615047A4 (en) 2021-01-13
US12133849B2 (en) 2024-11-05
US20240131025A1 (en) 2024-04-25
BR112019022308A2 (pt) 2020-05-26
US11364235B2 (en) 2022-06-21
EP3615047A1 (en) 2020-03-04
US20220273648A1 (en) 2022-09-01
US11844799B2 (en) 2023-12-19
US20250017919A1 (en) 2025-01-16
US20200383974A1 (en) 2020-12-10
WO2018200841A1 (en) 2018-11-01
CN110612109A (zh) 2019-12-24
JP2023165952A (ja) 2023-11-17
MX2019012660A (es) 2020-07-27
CA3059752A1 (en) 2018-11-01
JP2020158544A (ja) 2020-10-01
US20240226095A9 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
US12133849B2 (en) Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic
US20250121105A1 (en) Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
Gill et al. Targeted radionuclide therapy in combined-modality regimens
JP7274646B2 (ja) 血液悪性疾患を処置するための低用量抗体に基づく方法
Coiffier Monoclonal antibody as therapy for malignant lymphomas
Illidge et al. Radioimmunotherapy in follicular lymphoma
Winter et al. Future treatment strategies for cancer patients combining targeted alpha therapy with pillars of cancer treatment: external beam radiation therapy, checkpoint inhibition immunotherapy, cytostatic chemotherapy, and brachytherapy
Skarbnik et al. Radioimmunotherapy in mantle cell lymphoma
Bast et al. Monoclonal serotherapy
US20230302168A1 (en) Dr5 radioimmunotherapy in the treatment of solid cancers
HK40018488A (en) Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
Parihar et al. Radionuclide therapy of lymphomas
US20240299600A1 (en) Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225
Jacene et al. Radionuclide therapy of lymphomas
Kauffman Preclinical Development of Alpha-Particle Therapeutics
Carswell et al. 90Y ibritumomab tiuxetan
Chatterjee et al. Immunotherapeutic Strategies, Radiotherapy, and Targeted Radionuclide Therapy Approaches for the Treatment of Multiple Myeloma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221114

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221114

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230105

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230127

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250130

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250905